par Moreau, Michel 
;Klastersky, Jean ;Schwarzbold, A;Muanza, Frédérique;Georgala, Aspasia ;Aoun, Michel ;Loizidou, A;Barette, Martine;Costantini, Sabrina;Delmelle, Michel;Dubreucq, L;Vekemans, Marc ;Ferrant, Augustin;Bron, Dominique ;Paesmans, Marianne
Référence Annals of oncology, 20, 3, page (513-519)
Publication Publié, 2009-03
;Klastersky, Jean ;Schwarzbold, A;Muanza, Frédérique;Georgala, Aspasia ;Aoun, Michel ;Loizidou, A;Barette, Martine;Costantini, Sabrina;Delmelle, Michel;Dubreucq, L;Vekemans, Marc ;Ferrant, Augustin;Bron, Dominique ;Paesmans, Marianne Référence Annals of oncology, 20, 3, page (513-519)
Publication Publié, 2009-03
Article révisé par les pairs
| Résumé : | BACKGROUND: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. PATIENTS AND METHODS: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus >or= 1 day of FN)]. RESULTS: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2-8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface |
